COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

Show other versions (1)

Bibliographic Details
Main Authors:	A. V. Rudakova, V. A. Parfenov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	atrial fibrillation novel oral anticoagulants cost-effectiveness analysis apixaban warfarin acetylsalicylic acid
Online Access:	https://www.rpcardio.online/jour/article/view/233

Similar Items

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
by: Koretsune Y, et al.
Published: (2017-12-01)

Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
by: Chung-Ming Fu, et al.
Published: (2021-10-01)

APIXABAN – FROM RECOMMENDATIONS TO EVERYDAY PRACTICE
by: L. N. ELISEEVA, et al.
Published: (2016-12-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
by: Brandon K. Martinez, et al.
Published: (2018-04-01)

Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
by: Emre Ozdemir, et al.
Published: (2020-01-01)

Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On‐label Doses of Apixaban: J‐ELD AF Registry Subanalysis
by: Masato Okada, et al.
Published: (2021-08-01)

Apixaban
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
by: Krishna N. Pundi, et al.
Published: (2021-12-01)

Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis
by: Nobuaki Tanaka, et al.
Published: (2022-06-01)

CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01)

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
by: Mu-Mei Hu, et al.
Published: (2017-04-01)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012-05-01)

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation
by: Yutaro Mukai, et al.
Published: (2017-10-01)

The use of warfarin in veterans with atrial fibrillation
by: Rosenbeck Karen, et al.
Published: (2004-10-01)

Characteristics of warfarin under-prescription in older adults with atrial fibrillation
by: Sana Rashid, et al.
Published: (2021-12-01)

Modern features of the use of anticoagulants in cardiology
by: N. V. Dobryninа
Published: (2018-04-01)

Secondary prevention of stroke in atrial fibrillation, use of apixaban: ARISTOTLE, AVERROES studies
by: V.A. Parfenov, et al.
Published: (2014-10-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015-09-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
by: Dong Lin, et al.
Published: (2021-11-01)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
by: Badreldin HA, et al.
Published: (2020-07-01)

POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION
by: B. A. Tatarsky, et al.
Published: (2014-12-01)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
by: Hallinen T, et al.
Published: (2021-08-01)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
by: P. Fitzgerald, et al.
Published: (2020-05-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Balance of efficacy and safety in the prevention of stroke in patients with non-valvular atrial fibrillation: potential of apixaban. Questions and answers
by: I. S. Yavelov
Published: (2015-12-01)